Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. (NYSE: AVTR) is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. This news page aggregates company announcements, earnings updates and other disclosures so readers can follow how Avantor’s operations, portfolio and governance evolve over time.
Recent news releases describe Avantor’s participation in investor conferences, quarterly earnings reports, leadership and board appointments, and product and service developments. Examples include announcements about the timing of quarterly and full-year earnings releases and related conference calls, as well as participation in events such as the J.P. Morgan Healthcare Conference. These items provide context on how the company communicates with the investment community and presents its financial performance.
Product- and operations-focused news highlights areas such as bioprocessing, biomanufacturing and laboratory services. Avantor has reported the launch of a sterile sampling platform and PUPSIT assemblies for bioprocessing, the development of a biodegradable viral inactivation detergent recognized with an Edison Patent Award, and the expansion of its Centralized Service Center model with a facility serving the Greater Boston area. These updates illustrate how the company positions its tools and services within scientific and industrial workflows.
Corporate governance news includes the appointment of new directors and senior executives, such as additions to the Board of Directors and the creation of an Executive Vice President and Chief Operating Officer role. Together, these news items offer insight into Avantor’s strategic priorities, leadership changes and ongoing initiatives. Investors, analysts and industry participants can use this page to monitor company communications and official announcements over time.
Avantor, Inc. (NYSE: AVTR) reported its fourth-quarter and full-year 2022 financial results on February 3, 2023. The company achieved net sales of $1.80 billion for Q4, a 5.9% decline year-over-year, but saw core organic growth of 2.7%. Net income rose to $141.7 million. Full-year net sales reached $7.51 billion, up 1.7%, with core organic growth of 6.0%. Adjusted EBITDA was $1,570.7 million for the year, representing an 11.8% increase. Despite some regional sales decreases, strong performance in bioproduction and margin expansion were highlighted.
Avantor (NYSE: AVTR) and Avantor Foundation announced over $7 million in grants since 2009, focusing on STEM education and healthcare access. In 2022 alone, they donated more than $1 million to 15 organizations and provided over $1.3 million in products for education and disaster relief. The Foundation's recent initiatives included supporting STEM activities for over 2,000 youths in the UK and medical services for 5,000 children in Shanghai, China. Avantor is expanding employee engagement in community service, including matching donations and volunteer time.
Further details will be available in the 2023 Sustainability Report.
Avantor has entered into a multi-year supply and services agreement with Catalent to provide a wide range of laboratory supplies, clinical materials, and services. This partnership aims to enhance both companies' capabilities in delivering better treatments to patients and reflects their commitment to meeting global health needs. The collaboration builds on an existing relationship, showcasing Avantor's strengths in reliability and innovation.
Avantor, a leading global provider of mission-critical products and services, will announce its fourth quarter and full year 2022 financial results on February 3, 2023, before the market opens. A conference call to discuss these results will take place at 8:00 a.m. EST on the same day. Investors can access the live audio webcast through the company's Investors section on their website. A replay will be available for 30 days thereafter.
Avantor, Inc. (NYSE: AVTR) has announced that Michael Stubblefield, President and CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 12:45 p.m. EST. The presentation can be accessed via a live audio webcast by visiting the Events & Presentations section on Avantor's website. A replay will be available for 30 days after the event. Avantor provides essential products and services for life sciences and advanced technologies across over 180 countries, serving more than 225,000 customer locations.
Avantor, a global leader in critical products for life sciences and advanced technologies, announced that Michael Stubblefield, President and CEO, will engage in a fireside chat during the Evercore ISI HealthCONx conference on November 29, 2022, at 12:10 p.m. EST. Investors can access the live audio webcast on Avantor's website. A replay will be available for 30 days post-event. Avantor serves over 225,000 customers globally and is committed to advancing research and development across various industries.
Avantor, a global leader in mission-critical products and services, has opened a new distribution center in Dublin, Ireland, spanning nearly 69,000 square feet. This advanced facility enhances supply security for the biopharma market, creating 40 jobs and complementing the company's existing 76,000 square-foot presence in Ireland. This investment aligns with Avantor's strategy to expand its global footprint to meet increasing demand for essential biopharma products. The center will offer certified cGMP warehousing, clean rooms, and inventory solutions for improved customer service.
Avantor reported net sales of $1.86 billion, up 1.2% year-over-year, with core organic growth of 7.8%. The net income increased to $167 million, while adjusted EBITDA rose 6.9% to $384 million with a margin expansion to 20.7%. The operating cash flow was $258.3 million, and free cash flow was $219.3 million. Adjusted net leverage decreased to 3.6X. The company anticipates 2.5%-3.0% organic growth for the full year and updated adjusted EPS guidance to $1.38-$1.40.
Avantor, a global provider in life sciences and advanced technologies, will release its third quarter 2022 financial results on October 28, prior to market opening. A conference call will occur at 8:00 a.m. EDT on the same day to discuss these results. The company's extensive portfolio serves over 225,000 customer locations worldwide, supporting crucial research and development activities across numerous industries.
Avantor, Inc. (NYSE: AVTR) announced that its CEO, Michael Stubblefield, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 12, 2022, at 4:15 p.m. EDT. The session will be available via a live webcast on Avantor's investor website, with a replay accessible for 90 days post-event. Avantor is a global provider of critical products and services across various industries, serving over 225,000 customers globally.
FAQ
What is the current stock price of Avantor (AVTR)?
What is the market cap of Avantor (AVTR)?
